HGH Fragment 176-191

HGH Fragment 176-191 is a synthetic 16-amino-acid peptide corresponding to the C-terminal region of human growth hormone, designed to isolate growth hormone's lipolytic properties from its anabolic and diabetogenic effects. AOD-9604 (Anti-Obesity Drug 9604) is the Metabolic Pharmaceuticals development variant with an N-terminal tyrosine modification for stability. The compound stimulates lipolysis through the β3-adrenergic receptor pathway without engaging the GH receptor or elevating IGF-1. Six Phase 1 and 2 trials in approximately 900 participants confirmed safety, but the 2007 Phase 2b efficacy trial did not demonstrate sufficient weight loss for continued development. The compound is sold as a research chemical and used off-label for fat loss despite the failed human efficacy data. WADA prohibits the compound under Section S2.

Discovery and the Lipolytic Domain

In the early 1990s, researchers investigating the structure-function relationships of human growth hormone identified that the C-terminal region of the protein contained a lipolytic activity that was largely separable from the anabolic and diabetogenic activities mediated by the central GH-receptor-binding region. Specifically, amino acids 176 through 191 (the C-terminal 16-amino-acid sequence) appeared to retain the fat-mobilizing activity of GH while losing the growth-promoting activity.

This discovery suggested an attractive therapeutic strategy: synthesize the lipolytic fragment alone, achieve GH-like fat loss, avoid GH-like side effects (insulin resistance, IGF-1 elevation, soft-tissue overgrowth, carpal tunnel syndrome, joint pain). The fragment became known as HGH Fragment 176-191 or simply HGH Frag 176-191 or hexadecapeptide.

Metabolic Pharmaceuticals and AOD-9604

Metabolic Pharmaceuticals Limited, an Australian biotechnology company, took this discovery into formal pharmaceutical development. The company modified the native fragment by adding a tyrosine residue at the N-terminus to improve stability and resistance to proteolytic degradation. The modified compound was designated AOD-9604 (Anti-Obesity Drug 9604).

The Heffernan 2001 paper in Endocrinology established the foundational lipid-metabolism evidence for AOD-9604, showing comparable lipolytic effects to full GH in rodent adipose tissue.

Between approximately 2001 and 2007, Metabolic Pharmaceuticals conducted six Phase 1 and Phase 2 clinical trials of AOD-9604 in approximately 900 participants. The trial program included:

• Single-dose pharmacokinetic and safety studies
• Multiple-dose safety studies in healthy and overweight participants
• Dose-finding studies (300 mcg, 1 mg, higher doses tested)
• A Phase 2b efficacy trial in obese subjects

Safety Confirmed, Efficacy Failed

The cumulative trial data established an excellent safety profile:

• No serious adverse events attributed to the compound
• No IGF-1 elevation (the principal selectivity claim was validated)
• No glucose intolerance or insulin resistance
• Side effects comparable to placebo
• Well-tolerated at all doses tested up to 1 mg/day

The Stier et al. 2013 paper in the Journal of Endocrinology and Metabolism formally documented the safety findings.

The 2007 Phase 2b efficacy trial was the critical test for marketing development. The trial did not demonstrate sufficient weight-loss efficacy to justify continued development as an anti-obesity drug. Metabolic Pharmaceuticals announced the negative result via ASX disclosure and discontinued the AOD-9604 obesity program.

This was the principal turning point for the compound. Despite the mechanistic appeal (selective lipolytic activity without GH-like side effects) and the favorable safety data, the actual weight-loss magnitude in free-living humans was too small to support an obesity drug development pathway.

Why the Animal-to-Human Translation Failed

The pattern of strong rodent efficacy and weaker human efficacy is common in obesity drug development. The likely contributing factors for AOD-9604 specifically:

1. Compensatory appetite increases: rodent studies often use pair-feeding or controlled diets. Free-living humans can compensate for increased fat oxidation through increased caloric intake, blunting the weight-loss effect.
2. Neuroendocrine feedback loops: chronic AOD-9604 may downregulate β3-AR signaling or activate compensatory anabolic pathways.
3. Modest absolute lipolysis: even with reliable β3-AR activation, the absolute increase in fat oxidation may be insufficient to produce clinically meaningful weight loss in humans without diet change.
4. Species differences in β3-AR biology: human and rodent β3-AR signaling differ, and rodent adipose tissue is generally more β3-responsive than human adipose tissue.

The result is that the mechanism is real but the clinical magnitude in free-living humans is small.

Post-Metabolic Pharmaceuticals: Compounding Pharmacy Era

After Metabolic Pharmaceuticals abandoned the AOD-9604 development program, the compound entered a research-chemical and compounding-pharmacy market phase. US compounding pharmacies began producing AOD-9604 under FDA Section 503A bulk substance evaluations. Its status under 503A bulk substance rules has been contested by FDA at various times, with periods of permissive and restrictive enforcement.

Off-label use is concentrated in:

• Fat-loss-focused biohacker and bodybuilding communities
• Anti-aging and longevity clinics
• Aesthetic medicine for fat reduction (sometimes combined with cosmetic treatments)
• Weight-management protocols (often as a non-GLP-1 alternative)

In 2026, the rise of GLP-1 receptor agonists (semaglutide, tirzepatide) for weight loss has substantially reduced commercial and clinical interest in AOD-9604 as an obesity therapy. The newer agents produce 10 to 25 percent weight loss versus the small magnitude reported for AOD-9604 in human trials.

Off-Label Use Claims

Despite the failed Phase 2b efficacy result, off-label use of HGH Fragment 176-191 / AOD-9604 continues. Common claims in marketing and community discussions:

• Targeted fat loss, particularly from visceral fat
• "GH benefits without GH risks"
• Stackable with other peptides without endocrine concerns
• No suppression of natural GH or testosterone
• No anti-doping considerations (incorrect. See WADA section)
• Stackable with GLP-1 agonists or other fat-loss compounds

The mechanistic claims are largely supported by the preclinical and safety data. The efficacy claims are not supported by the Phase 2b clinical result.

Regulatory Status

• FDA: Not approved for any indication. Compounding pharmacy availability has fluctuated under 503A bulk substance evaluations.
• EMA: Not approved
• WADA: Prohibited under Section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) at all times in all sports
• TGA (Australia): Not approved for marketing

HGH Fragment 176-191's mechanism is centered on β3-adrenergic receptor signaling in adipose tissue, with notable selectivity for fat-related pathways over other GH-receptor-mediated pathways.

Selectivity vs Full GH

Full-length human growth hormone (191 amino acids) acts through the GH receptor, a single-pass transmembrane receptor that signals through JAK2/STAT5B and other pathways. GH receptor activation produces:

• IGF-1 elevation (liver and other tissues)
• Anabolic effects on muscle and bone
• Lipolysis in adipose tissue
• Insulin antagonism (diabetogenic effect at high doses)
• Soft-tissue growth (skin thickening, organ enlargement)

HGH Fragment 176-191 corresponds to the C-terminal region of GH that contains the lipolytic activity. Importantly:

• HGH Fragment 176-191 does not bind the GH receptor with significant affinity
• It does not raise IGF-1
• It does not produce anabolic effects on muscle
• It does not cause insulin resistance
• It is unlikely to produce acromegaly-like changes

The compound's effects are mediated through a different pathway, principally β3-adrenergic receptor signaling in adipose tissue.

β3-Adrenergic Receptor Mechanism

β3-adrenergic receptors (β3-AR) are Gs-coupled GPCRs predominantly expressed in adipose tissue (particularly brown adipose tissue and visceral white adipose tissue) and the bladder. β3-AR activation triggers:

• Adenylyl cyclase activation
• cAMP increase
• PKA activation
• Hormone-sensitive lipase (HSL) phosphorylation and activation
• Lipolysis (triglyceride breakdown to fatty acids and glycerol)
• Inhibition of lipogenic enzymes
• In brown adipose tissue: thermogenesis through UCP1 activation

The HGH Fragment 176-191 mechanism is thought to involve direct or indirect β3-AR engagement, with mechanistic studies showing that the long-term effects of AOD-9604 require functional β3-AR (knockout mice studies). The exact molecular interaction (whether HGH Frag binds β3-AR directly or through an upstream signaling step) is incompletely characterized.

Lipogenesis Inhibition

In addition to lipolysis, HGH Fragment 176-191 inhibits lipogenic activity in adipocytes. The molecular basis includes:

• Reduced acetyl-CoA carboxylase activity
• Reduced fatty acid synthase expression
• Reduced de novo lipogenesis

This dual effect (increased breakdown, reduced synthesis) creates a net catabolic state for adipose tissue.

Cartilage and Joint Effects (Secondary Investigation)

Some preclinical work has investigated AOD-9604's effects on cartilage repair and osteoarthritis, with mixed results. This is a secondary research area and is not the primary clinical or commercial focus.

Effects in preclinical models (rodent obesity studies):

• Reduced body weight gain in ob/ob mice and diet-induced obesity models
• Increased fat oxidation measurable by indirect calorimetry
• Increased lipolysis indices (plasma glycerol, free fatty acids)
• Preserved lean body mass during weight loss
• No insulin resistance development
• No IGF-1 elevation

Effects in human clinical trials (AOD-9604, Metabolic Pharmaceuticals program):

• Safety: excellent across all 6 trials, ~900 participants
• Tolerability: comparable to placebo
• IGF-1: no elevation (selectivity confirmed)
• Glucose tolerance: no impairment
• Weight loss (Phase 2b primary endpoint): insufficient to justify drug development. The exact magnitude is not consistently reported in the public summaries, but it was below the threshold for marketing pursuit.

Subjective effects reported in off-label use (uncontrolled, anecdotal):

• Modest fat loss, particularly with concurrent caloric deficit
• Some users report enhanced fat oxidation during cardio training
• Reduced subjective appetite in some users (mechanism unclear)
• No GH-like side effects (numb hands, joint stiffness, water retention)
• Best results reported in combination with diet, exercise, or GLP-1 RA stacks

Honest evidence framing: HGH Fragment 176-191 has an unusual evidence profile. Safety is well-established by Phase 2 clinical trials. Mechanism is plausible and selective (β3-AR-mediated lipolysis without GH side effects). Human efficacy is weak: the principal commercial development program (Metabolic Pharmaceuticals) abandoned the compound after Phase 2b due to insufficient weight loss. Off-label use continues despite this negative efficacy signal. In 2026, with GLP-1 RA producing 10 to 25 percent weight loss in obesity trials, AOD-9604's clinical relevance is limited.

Important note: HGH Fragment 176-191 has no FDA-approved dosing protocol. The doses described below are from Metabolic Pharmaceuticals clinical trials and off-label community protocols.

Standard research and off-label dose:

• Daily dose: 300 mcg subcutaneously, typically in the morning, fasted
• Maximum studied dose: 1 mg daily (Phase 2b)
• Cycle length: 12 weeks in clinical trials. Off-label use varies from 4 to 24 weeks

Timing rationale:

The morning fasted-state administration in off-label use is based on the rationale that:

• Insulin (elevated post-meal) inhibits lipolysis through the same pathway HGH Frag activates
• Pre-meal/fasted state maximizes the lipolytic effect window
• Combination with morning cardio is common in fat-loss protocols

There is no controlled comparison of timing strategies.

Routes:

• Subcutaneous is the route used in clinical trials and off-label use
• Intramuscular and intravenous routes are not used in off-label contexts due to the peptide nature and intended adipose tissue effect
• Oral and intranasal routes have been explored as research projects but are not commercially developed

Bioavailability and pharmacokinetics:

• Subcutaneous bioavailability is adequate but specific percentages are not well-reported in public sources
• Plasma half-life is short (peptide nature)
• Tyrosine modification (AOD-9604) extends stability compared to unmodified fragment

Reconstitution and storage:

• Lyophilized peptide reconstituted with bacteriostatic water or 0.9 percent sodium chloride
• Refrigeration after reconstitution
• Stability of reconstituted peptide: typically 2 to 4 weeks at 2-8°C
• Vendor quality varies in the research-chemical market

Special populations:

• Pregnancy and breastfeeding: not studied. Avoid
• Pediatric: not approved or studied. Avoid
• Active cancer: theoretical caution, though HGH Frag does not engage IGF-1 (which reduces this concern compared to other GH-related compounds)
• Athletes: WADA-prohibited
• Renal/hepatic impairment: not specifically studied

Adverse effects observed in clinical trials (n=~900):

• Side effects comparable to placebo
• No serious adverse events attributed to the compound
• Mild injection-site reactions (uncommon)
• Mild headache (occasional, no consistent excess over placebo)
• Mild gastrointestinal complaints (rare)
• No IGF-1 elevation (validated selectivity)
• No glucose intolerance
• No insulin resistance
• No fluid retention

Adverse effects reported in off-label use (uncontrolled):

• Mild injection-site reactions
• Mild fatigue or lethargy in some users
• Occasional headache
• Rare reports of palpitations (theoretical β-adrenergic mechanism)

Theoretical concerns:

• Cardiovascular: β3-AR activation could theoretically affect cardiovascular function, though clinical trial cardiovascular signals were not significant
• Bladder effects: β3-AR is expressed in bladder smooth muscle, and β3-AR agonists are used clinically (mirabegron) for overactive bladder. HGH Fragment's effects on bladder function have not been specifically characterized.
• Long-term safety: clinical trials were of limited duration (typically 12 weeks). Long-term (years) safety in continuous use is not characterized.
• Quality and identity: research-chemical market quality varies. AOD-9604 vs unmodified HGH Fragment 176-191 may be sold interchangeably with different actual chemistry.

Pregnancy and breastfeeding: avoid. No human pregnancy data.

Pediatric: not approved or studied. Avoid in patients under 18.

Athletes: WADA-prohibited under Section S2 at all times in all sports. Use carries doping-violation risk.

Notable safety advantage relative to other GH-related compounds:

The absence of IGF-1 elevation is a meaningful safety differentiator from full HGH or from GH secretagogues (CJC-1295, Ipamorelin, Tesamorelin). Compounds that raise IGF-1 carry theoretical cancer-pathway concerns and metabolic considerations (insulin resistance) that HGH Fragment 176-191 does not. For individuals concerned about IGF-1 elevation, HGH Fragment 176-191 is a more attractive option than GH or GH secretagogues, though its efficacy is also more limited.

HGH Fragment 176-191 sits in the fat-loss peptide category alongside GLP-1 receptor agonists, GH secretagogues, and various weight-management compounds. Its closest comparators:

• CJC-1295 with DAC and Ipamorelin: growth hormone secretagogues that increase endogenous GH (and IGF-1). Different mechanism (raise full GH biology). More potent body composition effects than HGH Fragment 176-191 but with the IGF-1 elevation that HGH Frag avoids.
• Tesamorelin: FDA-approved GHRH analog for HIV lipodystrophy. Reduces visceral fat through endogenous GH stimulation. The FDA-approved peer in the GH-related fat-loss category.
• Semaglutide (Ozempic, Wegovy) and Tirzepatide (Mounjaro, Zepbound): GLP-1 receptor agonists with FDA approval for type 2 diabetes (Ozempic, Mounjaro) and obesity (Wegovy, Zepbound). Different mechanism (GLP-1 RA, not lipolytic). Much greater human efficacy than HGH Frag 176-191. In 2026, these are the dominant pharmacological options for weight loss.
• 5-Amino-1MQ: NNMT inhibitor with metabolic effects. Different mechanism. Limited clinical evidence base.
• SLU-PP-332: ERR agonist with exercise-mimetic and metabolic effects. Different mechanism, preclinical only.

Common off-label stacks:

• HGH Fragment 176-191 + GLP-1 RA (semaglutide, tirzepatide): rationale of combining appetite suppression with direct lipolysis. No controlled trials, theoretically additive mechanisms.
• HGH Fragment 176-191 + CJC-1295/Ipamorelin: rationale of combining direct fat-tissue effects with endogenous GH pulse increase. Common in research-chemical "body recomposition" protocols.
• HGH Fragment 176-191 + Cardio training (fasted): behavioral protocol pairing morning fasted dosing with morning cardio. Mechanistically plausible but no controlled evidence.
• HGH Fragment 176-191 + Caloric restriction or intermittent fasting: positioned as an additive to lifestyle weight-loss strategies.

Combinations to avoid or use with caution:

• β-blocker therapy (especially β3-active): theoretical pharmacodynamic interaction
• Pregnancy and breastfeeding: avoid all weight-loss peptides
• Athletes subject to WADA testing: HGH Fragment use is a doping violation
• Active cancer: theoretical caution despite no IGF-1 elevation
• Severe cardiovascular disease: theoretical caution with any adrenergic-active compound

The most actionable framing of HGH Fragment 176-191 in 2026: this is a mechanistically interesting peptide with a clean safety record but a disappointing clinical efficacy record. The Phase 2b efficacy failure in 2007 was a meaningful negative signal that the GH-fragment-as-obesity-drug hypothesis did not translate from rodent models to free-living humans. In 2026, with semaglutide and tirzepatide producing 10 to 25 percent weight loss in obesity trials, AOD-9604's clinical relevance has narrowed substantially. Off-label use continues, primarily on mechanistic appeal and the absence of GH-like side effects rather than demonstrated human efficacy. Athletes should not use the compound due to WADA prohibition. For most individuals interested in fat loss, validated approaches (caloric restriction, exercise, GLP-1 RA if BMI-appropriate) provide better-supported risk/benefit profiles than HGH Fragment 176-191.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.